Your session is about to expire
← Back to Search
Moxonidine for Postural Orthostatic Tachycardia Syndrome (POTS)
Study Summary
This trial is studying whether a blood pressure medication can help improve symptoms in people with postural tachycardia syndrome, which mostly affects young women and causes significant disability.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not currently taking oral corticosteroids, have no infections, and am not using NSAIDs.I have a condition like heart disease, high blood pressure, I smoke, have high cholesterol, arthritis, or diabetes.I have had symptoms when standing for 6 months without any other sudden illness causing it.You have a body mass index (BMI) over 30.You are in the first half of your menstrual cycle, between days 5 and 13 of a 28-day cycle.I am between 18 and 55 years old.I have been diagnosed with a specific type of POTS based on nerve activity tests.I am between 18 and 55 years old.Your heart rate increases by 30 or more beats per minute when you stand up.I have a condition like diabetes that affects my nerves.I have hardening of the neck arteries or have had neck surgery.My heart rate increases significantly when I stand up, without a drop in blood pressure, and I've felt this way for over 6 months.I cannot stop taking my medication that affects my blood pressure or heart function.My physical fitness level is lower than expected for my age and sex.You are someone who smokes.
- Group 1: Moxonidine
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals able to join this research endeavor currently?
"Affirmative, the data on clinicaltrials.gov attests to this trial's active recruitment status. Initially posted August 27th 2019 and most recently edited January 19th 2022, it is now seeking 48 patients from a single medical centre."
What are the qualifications for participating in this clinical trial?
"This research trial seeks 48 participants, both male and female between the ages of 18-55, who have a history of marijuana abuse. Moreover, subjects must demonstrate an increase in heart rate by 30 beats per minute within 10 minutes after assuming an upright position as well as chronic symptoms associated with this posture for at least 6 months without any other acute cause present."
Does this clinical trial allow patients aged 70 or above to participate?
"As stated in the trial requirements, only individuals between 18 and 55 years of age are eligible for participation."
How many participants have enrolled in this scientific exploration?
"Affirmative. According to clinicaltrials.gov, this research is presently enrolling participants; the trial was first published in August of 2019 and was last updated on January 19th 2022. This medical study requires 48 people from a single site for inclusion."
Could you please provide an overview of research that has been conducted with Moxonidine?
"Currently, there are 5 ongoing clinical trials exploring the effects of Moxonidine with none in Phase 3. Nashville, Tennessee remains the epicenter for these investigations; however, other cities across America have also contributed to their advancement."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Share this study with friends
Copy Link
Messenger